New York's BeyondSpring Inc. appointed Edward Liu CFO.
Liu has more than a decade of senior banking experience, having served at J.P. Morgan and Jefferies. Prior to joining BeyondSpring, he served as partner and executive director at Epiphron Capital, an early investor in the company.
"His distinct blend of healthcare and in-depth financial expertise will be a key addition to the leadership team's collective experience as we advance toward our goal to submit New Drug Applications in China around year-end 2018/early 2019, and in the U.S. beginning in 2019," BeyondSpring CEO Lan Huang said in a statement.
BeyondSpring develops therapies for cancer using immuno-oncology.
BeyondSpring's lead asset, Plinabulin, is in a phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and two phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia.